Next Article in Journal
Gastroprotective and Antioxidant Activity of Kalanchoe brasiliensis and Kalanchoe pinnata Leaf Juices against Indomethacin and Ethanol-Induced Gastric Lesions in Rats
Next Article in Special Issue
VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease
Previous Article in Journal
ROS-Activated Ion Channels in Plants: Biophysical Characteristics, Physiological Functions and Molecular Nature
Previous Article in Special Issue
Vascular Endothelial Growth Factor-A Exerts Diverse Cellular Effects via Small G Proteins, Rho and Rap
Review

Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2

1
Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
2
Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands NG7 2UH, UK
3
CAPES-University of Nottingham Programme in Drug Discovery, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(4), 1264; https://doi.org/10.3390/ijms19041264
Received: 28 March 2018 / Revised: 14 April 2018 / Accepted: 16 April 2018 / Published: 23 April 2018
(This article belongs to the Special Issue Vascular Endothelial Growth Factor)
Vascular endothelial growth factor-A (VEGF-A) is a key mediator of angiogenesis, signalling via the class IV tyrosine kinase receptor family of VEGF Receptors (VEGFRs). Although VEGF-A ligands bind to both VEGFR1 and VEGFR2, they primarily signal via VEGFR2 leading to endothelial cell proliferation, survival, migration and vascular permeability. Distinct VEGF-A isoforms result from alternative splicing of the Vegfa gene at exon 8, resulting in VEGFxxxa or VEGFxxxb isoforms. Alternative splicing events at exons 5–7, in addition to recently identified posttranslational read-through events, produce VEGF-A isoforms that differ in their bioavailability and interaction with the co-receptor Neuropilin-1. This review explores the molecular pharmacology of VEGF-A isoforms at VEGFR2 in respect to ligand binding and downstream signalling. To understand how VEGF-A isoforms have distinct signalling despite similar affinities for VEGFR2, this review re-evaluates the typical classification of these isoforms relative to the prototypical, “pro-angiogenic” VEGF165a. We also examine the molecular mechanisms underpinning the regulation of VEGF-A isoform signalling and the importance of interactions with other membrane and extracellular matrix proteins. As approved therapeutics targeting the VEGF-A/VEGFR signalling axis largely lack long-term efficacy, understanding these isoform-specific mechanisms could aid future drug discovery efforts targeting VEGF receptor pharmacology. View Full-Text
Keywords: angiogenesis; endothelial cells; blood vessel; splicing; receptor tyrosine kinase inhibitors angiogenesis; endothelial cells; blood vessel; splicing; receptor tyrosine kinase inhibitors
Show Figures

Graphical abstract

MDPI and ACS Style

Peach, C.J.; Mignone, V.W.; Arruda, M.A.; Alcobia, D.C.; Hill, S.J.; Kilpatrick, L.E.; Woolard, J. Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. Int. J. Mol. Sci. 2018, 19, 1264. https://doi.org/10.3390/ijms19041264

AMA Style

Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ, Kilpatrick LE, Woolard J. Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. International Journal of Molecular Sciences. 2018; 19(4):1264. https://doi.org/10.3390/ijms19041264

Chicago/Turabian Style

Peach, Chloe J., Viviane W. Mignone, Maria A. Arruda, Diana C. Alcobia, Stephen J. Hill, Laura E. Kilpatrick, and Jeanette Woolard. 2018. "Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2" International Journal of Molecular Sciences 19, no. 4: 1264. https://doi.org/10.3390/ijms19041264

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop